Human papillomavirus type 16 antigens (HPV16 antigens) (HPV16 antigens)

Human papillomavirus type 16 (HPV16) antigens are viral proteins that serve as the primary targets for both the prevention and treatment of HPV-associated malignancies. The most significant antigens include the late capsid protein L1 and the early oncoproteins E6 and E7 (UniProt, 2024). L1 is the major structural component of the viral capsid and is used in prophylactic vaccines to induce neutralizing antibodies that block viral infection (CDC, 2021). E6 and E7 are the primary drivers of oncogenesis; E6 promotes the degradation of the tumor suppressor p53, while E7 binds and inactivates the retinoblastoma protein (pRb), collectively leading to cell cycle deregulation and malignant transformation (PubMed, 2023). Because E6 and E7 are constitutively expressed in HPV-positive cancer cells, they are targeted by therapeutic vaccines designed to elicit T-cell-mediated destruction of tumors (National Cancer Institute, 2023). HPV16 is recognized as the most oncogenic HPV type, responsible for the majority of cervical, anal, and oropharyngeal cancers worldwide (WHO, 2023).

Other names

HPV-16 E6HPV-16 E7HPV-16 L1HPV-16 L2HPV16 oncoproteinsHPV16 capsid proteins

Prophylactic vaccines utilize recombinant L1 capsid proteins to form virus-like particles (VLPs) that induce neutralizing antibodies, preventing viral entry into host cells (CDC, 2021). Therapeutic vaccines target the E6 and E7 oncoproteins to stimulate CD8+ and CD4+ T-cell-mediated immune responses, leading to the destruction of HPV-infected or malignant cells (National Cancer Institute, 2023).